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Abstract
Background: Trans fat are not desirable in many aspects on health maintenance. Low trans structured fats have
been reported to be relatively more safe than trans fats.
Methods: We examined the effects of low trans structured fat from corn oil (LC), compared with high trans fat
shortening, on cholesterol and fatty acid metabolism in apo E deficient mice which is an atherogenic animal
model. The animals were fed a high trans fat (10% fat: commercial shortening (CS)) or a low trans fat (LC) diet for
12 weeks.
Results: LC decreased apo B and hepatic cholesterol and triglyceride concentration compared to the CS group but
significantly increased plasma total cholesterol and triglyceride concentration and fecal lipids with a simultaneous
increase in HDL-cholesterol level, apo A-I, and the ratio of HDL-cholesterol to total cholesterol (HTR). Reduction of
hepatic lipid levels by inclusion of LC intake was observed alongside modulation of hepatic enzyme activities
related to cholesterol esterification, fatty acid metabolism and fecal lipids level compared to the CS group. The
differential effects of LC intake on the plasma and hepatic lipid profile seemed to be partly due to the fatty acid
composition of LC which contains higher MUFA, PUFA and SFA content as well as lower content of trans fatty
acids compared to CS.
Conclusions: We suggest that LC may exert a dual effect on plasma and hepatic lipid metabolism in an
atherogenic animal model. Accordingly, LC, supplemented at 10% in diet, had an anti-atherogenic effect on these
apo E
-/- mice, and increased fecal lipids, decreased hepatic steatosis, but elevated plasma lipids. Further studies are
needed to verify the exact mode of action regarding the complex physiological changes and alteration in lipid
metabolism caused by LC.
Introduction
Fat in foods has great palatability and can be addictive
to animals [1,2] and human beings [3]. Fats and oils as
they exist in nature must be processed before they are
suitable for human consumption [4]. Partial hydrogena-
tion of vegetable oils is a common technological aid to
food processing with few or no undesirable effects
although it can alter the composition of fatty acids.
Types of polyunsaturated fatty acids (PUFA) in dietary
fats have been shown to profoundly influence lipid
metabolism and physiological function. In particular,
linoleic acid (18:2, n-6, LA) and a-linolenic acid (18:3,
n-3) are metabolized to highly unsaturated fatty acids
which have distinct physiological functions [5]. However,
epidemiological evidence suggests a strong relationship
between the intake of trans fatty acids, which are
formed during the hydrogenation process, and the risk
of coronary heart disease (CHD) [6-8]. The effect of
trans fatty acids on the serum lipoprotein profile is at
least as unfavorable as that of cholesterol-raising
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any medium, provided the original work is properly cited.saturated fatty acids, because trans fatty acids not only
raise low-density lipoprotein (LDL) cholesterol levels
but also lower high-density lipoprotein (HDL) choles-
terol levels. Later studies, involving either partially
hydrogenated fat as the source of trans fatty acids or
specifically synthesized fat differing in only a single fatty
acid, further demonstrate the blood cholesterol raising
effects of trans fatty acids [9-12].
In this study, we attempted to synthesize a novel struc-
tured lipid using corn oil. LA is the primary (in terms of
mass consumed) essential fatty acid in corn oil. It can
reduce plasma total cholesterol and LDL-cholesterol
[13,14], each of which is an established CHD risk factor.
In the present study, the novel structured lipid was pro-
duced from corn oil by lipase-catalyzed glycerolysis,
which produced a lipid rich in monounsaturated fatty
acid (MUFA) and PUFA compared to trans fats. This
novel structured lipid may provide a beneficial effect on
lipid metabolism. Accordingly, we examined the physiolo-
gical effects of our novel structured lipid on the plasma
and hepatic lipid profile in apo E
-/- mice, an animal
model of atherosclerosis.
Materials and methods
Test Oil
A commercial shortening (CS, New Orleans, USA) and
al o wtrans structured fat from corn oil (LC, Seoul,
Korea) were used in this study. 500 g oil blends of anhy-
drous butterfat (ABF), palm stearin (PS) and corn oil
(CO) (8/6/6 and 6/6/9, w/w/w) were added respectively
into a 1-L tank stirred-batch type reactor. The tank
height and diameter was 11 cm and 15 cm respectively.
The enzyme load was 10% of total substrates (50 g, w/
w). The reaction was stirred at 230 rpm by an impeller
(blade length: 9 cm; blade width: 3.3 cm) and stirrer
motor (M Tops MS-3060D, Korea). Lipozyme RM IM
and Novozyme 435 were used for blending mixture of
8/6/6 and 6/6/9 by mass (ABF/PS/CO). The reaction for
production of the modified-butterfat was carried out for
24 hr in a solvent-free system. Samples were withdrawn
during the reaction according to the time course, and
then filtered by PTFE syringe membrane filter (25 mm,
0.2 μm, Whatman, USA) to remove the enzyme for ana-
lysis. The fatty acid profile was analyzed for each fat
used (Table 1).
Animals and Diets
Twenty male apolipoprotein E-deficient (apo E
-/-) mice, a
well established animal model of atherosclerosis, were
imported from Jackson Laboratory (Bar Harbor, Maine,
USA) at 5 weeks of age. All the mice were individually
housed under a constant temperature (24°C) with 12 h
light/12 h dark cycle and fed a palletized commercial
chow diet for 1 week after arrival. The mice were then
randomly divided into two groups (n = 10) and fed the
AIN-76 (American Institute of Nutrition, 1977) basal diet
containing 10% (wt/wt) test oil for 12 weeks (Table 2).
Free access was given to food and water. Blood was
taken from a tail vein for the determination of plasma
total cholesterol and triglyceride concentration at 0, 3rd,
6th, 9th and 12th wks. Every day for the last 4 days, the
Table 1 Fatty acid composition of two dietary lipids, a
hydrogenated trans fat and a corn-oil based low trans
structured fat, used in animal experiment
(unit : %)
CS LC
14:00 0.11 0.71
16:00 13.42 35.81
16:01 0.07 0.07
18:00 11.56 15.65
18:01 12.64 24.07
18:02 5.39 22.72
18:03 0.22 0.55
20:00 0.06 -
20:01 0.25 -
18:1T 43.84 -
18:2T 11.91 -
18:3T 0.50 0.42
Total Trans 56.25 0.42
n-6 5.39 22.72
n-3 0.22 0.55
n-6/n-3 ratio 24.50 41.31
SFA 25.15 52.17
MUFA 12.71 24.14
PUFA 5.61 23.27
P/S 0.22 0.45
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; P/S, PUFA/SFA ratio.
CS, commercial shortening; LC, low trans structured fat from corn oil.
Table 2 Composition of experimental diets composed of
a hydrogenated trans fat and a corn-oil based low trans
structured fat (unit : % of diet)
Groups Ingredients CS LC
Casein 20 20
Methionine 0.3 0.3
Sucrose 50 50
Cone starch 10 10
Fiber 5 5
Test oils 10 10
Cholinebitartrate 0.2 0.2
Mineral mixture
a 3.5 3.5
Vitamin mixture
b 11
Total 100 100
aAIN-76 mineral mixture (Harlan Teklad Co., Madison, WI).
bAIN-76 vitamin mixture (Harlan Teklad Co.).
CS, commercial shortening; LC, low trans structured fat from corn oil.
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food consumption and body weight were measured daily
and weekly. At the end of the experimental period, the
mice were anesthetized with ketamine-HCl after food
was withheld for 14 hours. Blood samples were taken
from the inferior vena cava for plasma lipid analysis.
T h eo r g a n sa n da d i p o s et i s s u e sw e r er e m o v e da n d
rinsed with physiological saline. All samples were stored
at -70°C until analysis. This experimental design was
approved by the Ethics Committee of Kyungpook
National University for the care and use of laboratory
animals.
Plasma, hepatic and fecal lipid analysis
The plasma triglyceride, total cholesterol and HDL-cho-
lesterol concentrations were enzymatically determined
using a commercial kit (Sigma). The plasma apolipopro-
tein A-I (apo A-I), apolipoprotein B (apo B) and non-
esterified fatty acid (NEFA) were also measured using
commercial assay kits (Nitto Boseki Co. Ltd, Japan,
NEFA-Wako Pure Chemical Industries). The hepatic
lipids were extracted using the procedure developed by
Folch et al. [15]. The dried lipid residues were dissolved
in 1 ml of ethanol for cholesterol and triglyceride assays.
Triton X-100 and a sodium cholate solution (in distilled
H2O) were added to 200 μL of the dissolved lipid solu-
tion to produce final concentrations of 5 g/L and
3 mmol/L, respectively. The hepatic cholesterol and tri-
glycerides were analyzed with the same enzymatic kit as
used in the plasma analysis.
The feces from each group were collected daily for 1
week and analyzed for lipids, as described previously
with a slight modification [15]. Briefly, the feces were
dried and extracted in ice-cold chloroform and metha-
nol (2:1, v/v) for 24 h at 4°C. After centrifugation at
900 × g for 10 min, the supernatant was collected, dried
at 50°C, and dissolved with ethanol. The fecal choles-
terol and triglyceride levels were estimated using the
same method as used for the liver.
Preparation of hepatic tissue enzyme source
Enzyme source fractions from hepatic tissue were pre-
pared as follows. The tissue 0.5 g was homogenized in a
fivefold volume of 0.25 M sucrose buffer and centrifuged
at 600 × g for 10 min to remove any cell debris and then
the supernatant was centrifuged at 10,000 × g for 20 min
to isolate the mitochondrial pellet. Finally, the superna-
tant was further ultracentrifuged at 105,000 × g for
60 min to obtain the cytosol supernatant. Protein con-
tents in the mitochondrial and cytosolic fractions were
measured according to the method of Bradford [16]
using bovine serum albumin as the standard.
Hepatic lipid regulating enzyme activities
Glucose-6-phosphate dehydrogenase (G6PD) activity
was assayed by spectrophotometric methods according
to the procedures described by Pitkanen et al. [17],
where the activity was expressed as the reduced
NADPH (nmol/min/mg protein). The supernatant cyto-
solic fractions were analyzed for malic enzyme (ME)
(EC 1.1.1.40) using modification of the methods of
Ochoa [18]. ME activity was expressed as nmol NADPH
(nmol/min/mg protein). The hepatic b-oxidation was
measured spectrophtometrically by monitoring the
reduction of NAD to NADH in the presence of palmi-
toyl-CoA [19]. The reaction was initiated by addition of
the enzyme source to a reaction cuvette containing 20
mM NAD, 0.33 M dithiothreitol, 1.5% bovine serum
albumin, 2% Triton X-100, 10 mM CoA, 1 mM FAD,
100 mM KCN, and 5 mM palmitoyl-CoA in 50 mM
Tris-HCl (pH 8.0). The reaction compartment was ther-
mostatted at 37°C, and the reaction rate was followed at
340 nm. Data were expressed as nmol of NAD reduced/
min/mg of protein. The carnitine palmitoyl transferase
(CPT) activity was determined according to the method
of Markwell et al. [20]. The results were expressed as
nmol/min/mg protein.
3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase and
acyl-CoA:cholesterol acyltransferase (ACAT) activities
The HMG-CoA reductase activity in the microsomal
fraction was measured with [
14C]HMG-CoA as the sub-
strate based on a modified method of Shapiro [21],
where the activity was expressed as the synthesized
mevalonate (pmol/min/mg protein). The ACAT activity
in the microsomes was determined by the rate of incor-
poration of [
14C]oleoyl-CoA into the cholesterol ester
fraction, as described by Erickson [22], where the activ-
ity was expressed as synthesized cholesteryl oleate
(pmol/min/mg protein).
Hepatic Tissue Morphology
Livers were removed and fixed in a buffer solution of
10% formaldehyde. Fixed tissues were processed routi-
nely for paraffin embedding, and 4-μms e c t i o n sw e r e
prepared and dyed with hematoxylin-eosin. Stained
areas were viewed using an optical microscope × 100
magnification.
Statistical analysis
All data are presented as the mean ± S.E. Statistically
significant differences between the groups were deter-
mined with a Student’s t test (p < .05) using the stan-
dard social science statistical package (SPSS, Chicago,
IL, USA).
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Food intake, weight gain, FER and organ weights
Weight gain and food efficiency ratio (FER) were signifi-
cantly higher in the LC group compared to the CS
group, with no change in food intake. The weight of
liver and heart (g/100 g body weight) was significantly
lower in the LC group than in the CS group (Table 3).
Plasma, hepatic and fecal lipids
The plasma total cholesterol and triglyceride levels were
significantly higher in the LC group (Table 4). While free
fatty acid concentration was unchanged. The HDL-
cholesterol, apo A-I, fecal lipids concentrations and the
ratio of HDL-cholesterol to total cholesterol were also
significantly higher in the LC group compared to the CS
group (Table 4). In addition, hepatic triglyceride, hepatic
cholesterol, apo B concentration and atherogenic index,
which are all significant risk factors of coronary heart dis-
ease, were significantly lower in the LC group (Table 4).
Enzyme activities related to fatty acid metabolism in liver
The hepatic and adipocyte G6PD and ME activity were
significantly lower in the LC group compared to the CS
groups (Table 5). The activity of hepatic b-oxidation
and CPT, the rate-limiting enzyme in fatty acid oxida-
tion, was significantly higher in the LC group compared
to the CS group (Table 5).
Hepatic HMG-CoA reductase and ACAT activities
The hepatic ACAT activity was significantly lower in the
LC supplemented group than in the CS group, while the
h e p a t i cH M G - C o Ar e d u c t a s ea c t i v i t yw a sn o ts i g n i f i -
cantly between the groups (Figure 1).
Morphological changes in hepatocytes
Lipid droplet accumulation in liver was lower in the LC
group compared to the CS group when observed in the
light microscope (Figure 2). This result was consistent
with the hepatic triglyceride and cholesterol profile
shown in Table 4.
Discussion
The present study demonstrates the differential effect of
two solid fats, a low trans structured fat and a hydroge-
nated trans fat, on plasma and hepatic lipid metabolism
in apo E
-/- mice. Trans fatty acid intake has been con-
vincingly shown to be associated with a significantly
higher risk of heart disease based on large epidemiology
Table 3 Effect of supplementation of a hydrogenated
trans fat and a corn-oil based low trans structured fat on
food intake, weight gain, food efficiency ratio (FER) and
organ weights in apo E
-/- mice
Group CS LC
Food Intake (g/day) 4.32 ± 0.09 4.35 ± 0.11
Weight gain (g/day) 0.12 ± 0.01 0.15 ± 0.01**
FER 0.03 ± 0.00 0.03 ± 0.00*
Organ Weights (g/100 g B.W.)
Liver 6.78 ± 0.29 5.21 ± 0.08***
Heart 0.46 ± 0.01 0.37 ± 0.02**
Data are mean ± S.E. (n = 10).
Values are significantly different from the CS group according to Student’s t
test: *P < .05, **P < .01, ***P < .001.
FER : Food efficiency ratio = body weight gain/food intake; B.W., Body Weight
CS, commercial shortening; LC, low trans structured fat from corn oil
Table 4 Effect of supplementation of a hydrogenated
trans fat and a corn-oil based low trans structured fat on
plasma, hepatic and fecal lipid levels in apo E
-/- mice
CS LC
Plasma lipids
Free fatty acid (mmol/L) 1.14 ± 0.03 1.11 ± 0.04
Triglyceride (mmol/L) 1.46 ± 0.09 2.09 ± 0.08***
Total-C (mmol/L) 16.45 ± 0.81 18.75 ± 0.37*
HDL-C (mmol/L) 0.11 ± 0.02 0.81 ± 0.06***
HDL-C/Total-C (%) 0.60 ± 0.06 4.06 ± 0.39***
Atherogenic index
a 174.95 ± 18.05 23.39 ± 1.99***
Apo A-I (mg/dL) 4.46 ± 0.57 7.47 ± 0.25***
Apo B (mg/dL) 21.00 ±0.54 17.19 ± 0.60***
Hepatic lipids
Cholesterol (mmol/g liver) 7.88 ± 0.03 5.83 ± 0.19***
Triglyceride (mmol/g liver) 7.21 ± 0.34 5.27 ± 0.18**
Fecal lipids
Cholesterol (μmol/g) 4.60 ± 0.28 6.44 ± 0.37**
Triglyceride (μmol/g) 2.22 ± 0.54 4.44 ± 0.85*
Data are mean ± S.E. (n = 10). Values are significantly different from the CS
group according to Student’s t test: *P < .05, **P < .01, ***P < .001. C:
cholesterol.
a Atherogenic index: (Total-C-HDL-C)/HDL-C
CS, commercial shortening; LC, low trans structured fat from corn oil.
Table 5 Effect of supplementation of a hydrogenated
trans fat and a corn-oil based low trans structured fat on
the enzyme activities related to the hepatic fatty acid
metabolism in apo E
-/- mice
CS LC
Fatty acid synthesis
G6PD (nmol/min/mg protein) 24.90 ± 2.74 7.42 ± 0.30
***
ME (nmol/min/mg protein) 217.4 ±
18.64
126.58 ±
15.32
**
Fatty acid oxidation
b-oxidation (μmol/min/mg
protein)
0.43 ± 0.08 5.42 ± 1.13
*
CPT (nmol/min/mg protein) 19.86 ± 1.42 27.09 ± 1.56
**
Data are mean ± S.E. (n = 10). Values are significantly different from the CS
group according to Student’s t test: *P < .05, **P < .01, ***P < .001. G6PD,
glucose-6-phosphate dehydrogenase; ME, malic enzyme; CPT, carnitine
palmitoyl transferase.
CS, commercial shortening; LC, low trans structured fat from corn oil.
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sive review of past studies summarized trans fatty acid
intake significantly effects blood lipids, in particular the
LDL-cholesterol/HDL-cholesterol ratio and total choles-
terol/HDL-cholesterol ratio, leading to increased risk of
CHD risk [26]. In the present study, plasma HDL-
cholesterol, apo A-I concentrations and HTR were
significantly increased, whereas apo B level were significantly
l o w e ri nt h eL Cg r o u pt h a ni nt h eC Sg r o u p .A p oBa n da p o
A-I are thought to be better predictors of CHD risk than
total cholesterol and LDL-cholesterol [27]. Apo A-I also acts
as a cofactor for lecithin: cholesterol acyltransferase (LCAT)
[28], which is an important enzyme involved in removing
excess cholesterol from tissues and incorporating it into
HDL for reverse cholesterol transport to the liver [29]. Apo
B is synthesized in the liver and is present in LDL, IDL and
VLDL particles [29], and therefore the total apo B concen-
tration indicates the amount of potentially atherogenic lipo-
proteins in plasma or liver [30].
Previous studies have shown that eating partially hydro-
genated lipids results in an increase in liver phospholipid
concentrations [31]. In the present study, hepatic choles-
terol, triglyceride and lipid droplet accumulation in liver
was also significantly lowered in the LC group than in
the CS group which may contribute reducing liver
weight. Hence LC consumption appears to prevent the
development of hepatic steatosis in apo E deficient mice.
Elevated excretion of cholesterol and triglyceride was also
observed in LC fed mice. However, plasma total-C and
triglyceride concentration were significantly higher in the
LC group than in the CS group. It is plausible that the
difference in fatty acid composition between CS and LC
could have led to the paradoxical finding of an anti-
arterogenic effect in liver but negative pro-arteriogenic
effect in blood although at present the mechanism is
unclear. A commercial low trans fat with high MUFA,
myristic acid and palmitic acid content also exhibited the
same hepatic lipid-lowering effect but paradosical
increase in the plasma cholesterol concentration [32].
Current findings support the dual effects of low trans
fats, in part, can be modulated by the fatty compositions
of these structured fats. Saturated fatty acids (SFAs) are
Figure 1 Effect of supplementation of a hydrogenated trans fat
and a corn-oil based low trans structured fat on HMG-CoA
reductase (HMGR) and ACAT activities in apo E
-/- mice : CS
group (■) and LC group (□). The results represent mean ± S.E. (n
= 10). Values are significantly different from the CS group according
to Student’s t test: *P < .05. HMGR, 3-hydroxy-3-methylglutaryl-
coenzyme reductase; ACAT, acyl CoA: cholesterol acyltransferase. CS,
commercial shortening; LC, low trans structured fat from corn oil.
Figure 2 Effect of supplementation of a hydrogenated trans fat and a corn-oil based low trans structured fat on hepatic tissue
morphology in apo E
-/- mice. The results represent mean ± S.E. (n = 10). The results represent mean ± S.E. (n = 10). Original magnification ×
100. Fat accumulation, indicated by the arrowheads, in the form of large fat droplet is present in liver. CS, commercial shortening; LC, low trans
structured fat from corn oil.
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concentration [33]. The cholesterol raising properties of
SFAs can be primarily attributed to myristic acid (14:0)
and palmitic acid (16:0). These SFAs may have different
effects on serum total cholesterol concentrations [34].
Replacing SFA with MUFA reduces total cholesterol,
LDL-cholesterol, and triglyceride concentrations [35].
Alternatively, the differential effects of low trans fat on
lowering hepatic lipids in apo E
-/- mice can be attributed
to their specific fatty acid composition. The CS contains
more trans fatty acid and less SFA per se in comparison
to LC which is rich in linoleic acid, however in MUFA
a n dP U F Av i c ev e r s ai st r u ea n dt h er e l a t i v ea m o u n to f
SFA is higher.
Regarding cholesterol metabolism, dietary LC did not
significantly lower hepatic HMG-CoA reductase activity,
however LC significantly decreased hepatic ACAT activ-
ity. HMG-CoA reductase is the rate-limiting enzyme in
the cholesterol biosynthetic pathway that converts
HMG-CoA to mevalonate [36,37]. Intracellular choles-
teryl ester (CE) synthesis catalyzed by ACAT serves to
store cholesterol in cytosolic droplets and also partici-
pates in the hepatic secretion of lipoproteins containing
apo B [38-40]. Moreover,A C A Ti sb e l i e v e dt ob e
involved in cholesterol absorption from the intestine
[41] although this was beyond the scope of the present
study. Under pathological conditions, the chronic accu-
mulation of CE produced by ACAT in macrophages and
arterial smooth muscle cells leads to the characteristic
foam cell formation in atherosclerosis [42]. Therefore,
ACAT inhibitors are also expected to be cholesterol-
lowering and hence potential anti-atherosclerotic agents.
In summary, an increased hepatic fatty acid synthesis
was correlated with the availability of fatty acids for tri-
glyceride synthesis [43]. The activities of two hepatic
enzymes G6PD and ME, related to fatty acid synthesis,
were lower in the LC supplemented apo E
-/- mice in
this study. Taken together these findings suggest that
the LC supplement had a hepatic triglyceride-lowering
effect via lowering the hepatic lipogenic enzyme activ-
ities while elevating the hepatic CPT and b-oxidation
activity in the apo E
-/- mice.
Conclusions
In conclusion, this study provides evidence that low
trans structured fat from corn oil reduces hepatic lipid
accumulation via inhibition of lipogenesis while elevat-
ing fatty acid oxidation in apo E
-/- mice, a model for
atherosclerosis. The differential effects of LC observed
on the plasma and liver lipid profile seem to be partly
due to the fatty acid composition of LC compared to
C S ,a sL Ci sh i g hi nS F A ,M U F Aa n dP U F Ac o n t e n t .
High SFA in LC may explain the unfavorable effect of
LC on plasma triglyceride concentration. We suggest
that LC exerts both an anti-atherosclerotic and pro-
atherosclerotic effect on plasma and liver lipid metabo-
lism in an atherogenic susceptible animal model. How-
ever, further studies are required to verify differential
the effects of specific fatty acid composition in low trans
fats, on lipid metabolism, to justify recommendations to
use low trans fats such as LC in food processing.
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